NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
TrumpTariffTradeAnnounceLaunchNewsPricesStrikesMajorFebruaryPhotosYourCarLotSayCourtDigestSundayTimelineSafetyGlobalMarketTechChina
TrumpTariffTradeAnnounceLaunchNewsPricesStrikesMajorFebruaryPhotosYourCarLotSayCourtDigestSundayTimelineSafetyGlobalMarketTechChina
All Articles
STAT+: At drugmakers’ forum, Oz gets a friendly embrace, while Makary faces tough questions
STAT News
Published 5 days ago

STAT+: At drugmakers’ forum, Oz gets a friendly embrace, while Makary faces tough questions

STAT News · Feb 17, 2026 · Collected from RSS

Summary

Two of health secretary Robert F. Kennedy Jr.’s top lieutenants struck decidedly different tones at a forum held Tuesday by the pharmaceutical industry group PhRMA.

Full Article

WASHINGTON — Two of health secretary Robert F. Kennedy Jr.’s top lieutenants struck decidedly different tones at a forum held Tuesday by the pharmaceutical industry group PhRMA. The administrator of the Centers for Medicare and Medicaid Services, Mehmet Oz, had a friendly on-stage conversation with Pfizer CEO and PhRMA board chair Albert Bourla in which he spoke of the benefits of vaccines, welcomed the idea of closed-door meetings with executives to hammer out policy ideas, and even suggested industry leaders should consider government jobs, despite Kennedy’s own criticism of the “revolving door” between government and industry. Food and Drug Administration Commissioner Marty Makary, on the other hand, was grilled by former CNBC reporter Bertha Coombs about the agency’s more skeptical approach to the regulation of vaccines, including the recent decision by top official Vinay Prasad to refuse to review Moderna’s application for a new flu shot. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe


Share this story

Read Original at STAT News

Related Articles

STAT News1 day ago
STAT+: Nature Medicine to investigate study that found cancer treatment is better in morning

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

STAT News2 days ago
STAT+: DOJ, Ohio attorney general accuse OhioHealth of driving up prices, crowding out competition

Regulators say Ohio hospital system made it difficult for health insurers to offer cheaper plans.

STAT News2 days ago
STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

STAT News2 days ago
STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

And other biotech news brought to you by The Readout newsletter

STAT News2 days ago
STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV

STAT News2 days ago
ACIP meeting postponed, for reasons that are unclear

And other health news from today's Morning Rounds newsletter